Nadia Belmatoug


Country: France


  1. Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017;37:25-32 pubmed publisher
    ..Physicians will need to carefully assess individual Gaucher patients to determine their appropriateness for eliglustat therapy. The therapeutic response to eliglustat and use of concomitant medications will require long-term monitoring. ..
  2. Lau H, Belmatoug N, Deegan P, Goker Alpan O, Schwartz I, Shankar S, et al. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. Blood Cells Mol Dis. 2018;68:226-231 pubmed publisher
    ..These observations, in addition to information in the literature, suggest that continuation of ERT during pregnancy may be appropriate for GD patients. ..
  3. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci. 2017;18: pubmed publisher
    ..Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat). ..
  4. Biegstraaten M, Cox T, Belmatoug N, Berger M, Collin Histed T, Vom Dahl S, et al. Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis. 2018;68:203-208 pubmed publisher
    ..When applying this set of goals in medical practice, the clinical status of the individual patient should be taken into account. ..